Says continues to manage Humira erosion from biosimilars. Says several promising R&D programs in the pipeline. Expects “robust” revenue growth in 2025 and strong CAGR through the end of the decade. Says Botox continues to perform “very well” despite competition. Comments taken from Q3 earnings conference call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- Abbvie Reports Earnings: Did it Beat Estimate Forecasts?
- AbbVie (NYSE:ABBV) Exceeds Q3 Expectations; Hikes Dividend
- AbbVie raises quarterly dividend 4.7% to $1.55 from $1.48 per share
- AbbVie raises FY24 EPS guidance floor from $10.70 to $11.00, consensus $10.45
- AbbVie Reports Third-Quarter 2023 Financial Results